Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label 52-week study of KRP-AB1102F DPI in COPD
jRCT2080222177Phase 3
- Sponsor
- Kyorin Pharmaceutical
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of KRP-AB1102F in chronic obstructive pulmonary disease (COPD), sponsored by Kyorin Pharmaceutical.
02
Drugs
KRP-AB1102F
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080222177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222177.